Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Commerce Bank

Commerce Bank boosted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 15.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,016 shares of the biotechnology company’s stock after buying an additional 274 shares during the quarter. Commerce Bank’s holdings in Sarepta Therapeutics were worth $252,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fifth Third Wealth Advisors LLC acquired a new position in Sarepta Therapeutics during the second quarter worth about $607,000. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Sarepta Therapeutics in the second quarter valued at about $4,771,000. Simplify Asset Management Inc. lifted its holdings in shares of Sarepta Therapeutics by 84.6% in the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after purchasing an additional 88,474 shares in the last quarter. Securian Asset Management Inc. purchased a new stake in shares of Sarepta Therapeutics in the second quarter valued at about $1,187,000. Finally, Natixis Advisors LLC purchased a new stake in shares of Sarepta Therapeutics in the second quarter valued at about $1,918,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on SRPT shares. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a report on Wednesday. HC Wainwright started coverage on shares of Sarepta Therapeutics in a research note on Monday. They set a “sell” rating and a $80.00 price objective on the stock. StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $175.77.

Insider Transactions at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This trade represents a 14.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $137.94 on Thursday. Sarepta Therapeutics, Inc. has a 52-week low of $78.67 and a 52-week high of $173.25. The firm has a fifty day moving average of $121.90 and a 200-day moving average of $131.39. The firm has a market capitalization of $13.18 billion, a P/E ratio of 104.40 and a beta of 0.81. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.